Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsForexCryptocurrenciesCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

share with twitter share with LinkedIn share with facebook
share via e-mail
11/25/2019 | 03:32am EST
FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel

Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc, Sanofi and Regeneron Pharmaceuticals.

Novartis is paying $85 per share in cash, a 24% premium over The Medicines Co's closing price of $68.55 on Friday, to acquire the U.S. biotechnology company's lone drug, the cholesterol-lowering injection inclisiran.

The deal shows Novartis CEO Vas Narasimhan is ready to spend billions on not just rare disease treatments, as it did in 2018 when it paid $8.7 billion for gene therapy specialist AveXis, but also for cardiovascular medicines aimed at a market with potentially millions of patients.

Inclisiran, which still must win regulators' approval, is set to require twice-yearly injections by doctors, far less frequently than the 26-injection regimens of Amgen's Repatha and Sanofi's and Regeneron's Praluent cholesterol-lowering drugs.

"We believe that will lead to less patient abandonment," Narasimhan told investors on a call on Monday. "Payers will have confidence knowing that physician administration will ensure patient compliance."

Novartis shares were seen up 0.2%, premarket indicators showed.

Repatha and Praluent, which similar to inclisiran aim to inhibit PCSK9 proteins that lead to elevated levels of bad LDL cholesterol in people with heart disease, have struggled to gain traction due a demanding dosing regiment as well as objections to their price, which makers have been forced to slash to less than $6,000 annually.

Narasimhan said he is confident that inclisiran can produce an attractive return on investment and contribute to sales starting in 2021, contingent upon regulatory approval and completion of the deal.

"We see returns well in excess of cost of capital," Chief Financial Officer Harry Kirsch said. Novartis plans to pay for with one-third cash and two-thirds long-term borrowings.

Inclisiran could become one of its best-selling medicines, Basel-based Novartis predicted, adding the transaction had been approved by the boards of both companies.

The acquisition would modestly dilute core earnings per share versus a no-deal scenario during the next few years, but should then be significantly accretive to group core operating income and core EPS in the medium term, Novartis said.

HEART DISEASE

Inclisiran, for use on top of statins by heart patients who struggle to lower their cholesterol levels with traditional therapy, is seen as complementing Novartis’s growing business with its heart-failure medicine Entresto, which topped the $1 billion annual revenue threshold last year.  

Narasimhan said the company can leverage the sales force it built up to help boost the initially slow Entresto sales to market inclisiran, too.

Novartis has historically had a strong cardiovascular drug franchise, but lost ground when Diovan, once a $6 billion-per-year seller, lost patent protection in 2012. It left the company without an immediate, innovative follow-up product.

The deal fits Narasimhan’s target of acquisitions of up to $10 billion to bolster the group's portfolio of medicines with new products or technologies.

Novartis' hunt for deals comes as billions in revenue is under threat from upcoming patent expirations including on Lucentis, for macular degeneration, iron overload medicine Exjade and $3.3 billion-per-year MS drug Gilenya.

Still, Novartis said it is confident that new products including inclisiran will help bolster growth and profitability.

It expects to expand core operating income margins in its Innovative Medicines division to the "mid-thirties" in the near term and to the "mid-to high-thirties" in the medium term.

By Silke Koltrowitz and John Miller

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. 0.16% 223.045 Delayed Quote.-7.30%
NOVARTIS 0.41% 95.79 Delayed Quote.4.05%
REGENERON PHARMACEUTICALS 0.69% 398.665 Delayed Quote.6.41%
SANOFI 0.35% 94.04 Real-time Quote.4.56%
THE MEDICINES COMPANY 0.00%End-of-day quote.-0.05%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
10:00aDERMAPHARM HOLDING SE : Acquisition of Allergopharma
EQ
10:00aDOVRE : pays additional consideration for the Tech4Hire acquisition and directs a share issue to the sellers of Tech4Hire
AQ
10:00aDERMAPHARM : to acquire Allergopharma
EQ
10:00aZontail Inc. Announces Non-Brokered Private Placement for up to $1,295,683
NE
09:58aBORREGAARD ASA : Stock options exercised, repurchase of own shares
AQ
09:57aWyndham Hotels' Board of Directors Investigated For Potential Breaches of Fiduciary Duty By Block & Leviton LLP
GL
09:56aAM BEST : to Exhibit at the 2020 Property & Liability Resource Bureau Claims Conference
BU
09:55aKORNIT DIGITAL : Q4 2019 Investor Presentation
PU
09:55aPREMIER MITON : Form 8.3 - Share plc - AMENDMENT
PU
09:55aGFINITY : and ViacomCBS in partnership for VidCon
PU
Latest news "Companies"